A trivalent gC2/gD2/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection

Highlights•Our goal is to produce antibodies to immune evasion domains through immunization. •Antibodies produced by HSV infection bind gC2 yet do not block gC2 binding to C3b. •Antibodies produced by immunization bind gC2 and prevent C3b from binding. •Immunizing infected animals produces gC2 antib...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2019-01, Vol.37 (4), p.664-669
Main Authors: Hook, Lauren M, Awasthi, Sita, Dubin, Jonathan, Flechtner, Jessica, Long, Deborah, Friedman, Harvey M
Format: Article
Language:English
Subjects:
Adjuvants
Adjuvants, Immunologic - administration & dosage
Allergy and Immunology
Aluminum sulfate
Animals
Antibodies
Antibodies, Neutralizing - blood
Antibodies, Viral - blood
Antigens
Blocking
Cell surface
Complement C3b
Complement C3b - immunology
CpG islands
Domains
Female
Genital herpes
Glycoprotein C
Glycoprotein D
Glycoproteins
Guinea Pigs
Herpes Genitalis - prevention & control
Herpes simplex
Herpes simplex virus
Herpes viruses
Herpesvirus 2, Human
Human subjects
Humans
Hypotheses
Immune Evasion
Immunization
Immunoglobulins
Infections
Inoculation
Laboratory animals
Proteins
Public health
Vaccine
Vaccine development
Vaccines
Viral Envelope Proteins - genetics
Viral Envelope Proteins - immunology
Viral Vaccines - administration & dosage
Viral Vaccines - immunology
Virions
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights•Our goal is to produce antibodies to immune evasion domains through immunization. •Antibodies produced by HSV infection bind gC2 yet do not block gC2 binding to C3b. •Antibodies produced by immunization bind gC2 and prevent C3b from binding. •Immunizing infected animals produces gC2 antibodies that prevent C3b from binding. •Vaccines make the weakly immunogenic immune evasion domains of gC2 more immunogenic.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2018.11.076